News
GSK (GSK) stock in focus as the FDA staff raise safety concerns over Blenrep combo for multiple myeloma ahead of an AdCom ...
The offering, the first IPO this year, attracted more than 32 billion dirhams ($3.5 bln) in demand for 500 million dirhams in shares. GSK seeks FDA nod for expanded use of RSV vaccine in adults ...
The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in ...
Asia Pacific active pharmaceutical ingredients (API) market will grow by 8.1% annually with a total addressable market cap of $ 1,098.6 billion over 2023-2032, driven by rising adoption of biologics ...
Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...
Syngene International Ltd., an integrated research, development, and manufacturing services organization, in partnership with ...
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- ...
Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are ...
Good morning, it’s the third of July. This newsletter will be off tomorrow for the holiday and — surprise — all of next week.
The announcement from the British pharmaceutical giant GSK and Indian drugmaker Bharat Biotech will therefore be a relief to those trying to balance the books. Closing the gap between supply and need ...
Bharat Biotech and GSK to reduce price of malaria vaccine for children to less than USD 5 by 2028.
Bharat Biotech and GSK will lower the malaria vaccine price to under $5 by 2028. This is due to better processes and more production. They pledged this to Gavi. Bharat Biotech invested over $200 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results